FDA OKs third antibody COVID therapy; variants spur new pause on another

Retrieved on: 2021-05-31 22:18:03

Tags for this article:

Medical specialties

Medicine

Clinical medicine

Antiviral drugs

Monoclonal antibodies

Immunology

COVID-19 drug development

Biotechnology

Bamlanivimab

Treatment and management of COVID-19

Regeneron Pharmaceuticals

Draft:Bamlanivimab

Click the tags to see associated articles and topics

FDA OKs third antibody COVID therapy; variants spur new pause on another. View article details on HISWAI: https://www.mcknights.com/news/clinical-news/fda-oks-third-antibody-covid-therapy-variants-spur-new-pause-on-another/

Excerpt

A new COVID-19 treatment made by GlaxoSmithKline now is the third ... virus variants, although its combination therapy remained in use at the time. ... by some geriatricians and industry advocates as a boon for long-term care ...

Article found on: www.mcknights.com

View Original Article